000153236 001__ 153236
000153236 005__ 20240229120023.0
000153236 0247_ $$2doi$$a10.1007/s10555-019-09839-9
000153236 0247_ $$2pmid$$apmid:31970591
000153236 0247_ $$2ISSN$$a0167-7659
000153236 0247_ $$2ISSN$$a1573-7233
000153236 0247_ $$2altmetric$$aaltmetric:74381358
000153236 037__ $$aDKFZ-2020-00269
000153236 041__ $$aeng
000153236 082__ $$a610
000153236 1001_ $$aKnott, Maximilian M L$$b0
000153236 245__ $$aTargeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
000153236 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2019
000153236 3367_ $$2DRIVER$$aarticle
000153236 3367_ $$2DataCite$$aOutput Types/Journal article
000153236 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662107336_29854$$xReview Article
000153236 3367_ $$2BibTeX$$aARTICLE
000153236 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153236 3367_ $$00$$2EndNote$$aJournal Article
000153236 500__ $$a2019 Dec;38(4):625-642LA:L701
000153236 520__ $$aWhile sarcomas account for approximately 1% of malignant tumors of adults, they are particularly more common in children and adolescents affected by cancer. In contrast to malignancies that occur in later stages of life, childhood tumors, including sarcoma, are characterized by a striking paucity of somatic mutations. However, entity-defining fusion oncogenes acting as the main oncogenic driver mutations are frequently found in pediatric bone and soft-tissue sarcomas such as Ewing sarcoma (EWSR1-FLI1), alveolar rhabdomyosarcoma (PAX3/7-FOXO1), and synovial sarcoma (SS18-SSX1/2/4). Since strong oncogene-dependency has been demonstrated in these entities, direct pharmacological targeting of these fusion oncogenes has been excessively attempted, thus far, with limited success. Despite apparent challenges, our increasing understanding of the neomorphic features of these fusion oncogenes in conjunction with rapid technological advances will likely enable the development of new strategies to therapeutically exploit these neomorphic features and to ultimately turn the 'undruggable' into first-line target structures. In this review, we provide a broad overview of the current literature on targeting neomorphic features of fusion oncogenes found in Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma, and give a perspective for future developments. Graphical abstract Scheme depicting the different targeting strategies of fusion oncogenes in pediatric fusion-driven sarcomas. Fusion oncogenes can be targeted on their DNA level (1), RNA level (2), protein level (3), and by targeting downstream functions and interaction partners (4).
000153236 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000153236 588__ $$aDataset connected to CrossRef, PubMed,
000153236 7001_ $$aHölting, Tilman L B$$b1
000153236 7001_ $$aOhmura, Shunya$$b2
000153236 7001_ $$0P:(DE-He78)fd68f49dada874ac262fadf9fde869df$$aKirchner, Thomas$$b3
000153236 7001_ $$aCidre-Aranaz, Florencia$$b4
000153236 7001_ $$0P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aGrünewald, Thomas$$b5
000153236 773__ $$0PERI:(DE-600)2004180-9$$a10.1007/s10555-019-09839-9$$n4$$p625-642$$tCancer and metastasis reviews$$v38$$x1573-7233$$y2019
000153236 909CO $$ooai:inrepo02.dkfz.de:153236$$pVDB
000153236 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153236 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER METAST REV : 2017
000153236 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153236 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153236 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153236 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153236 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153236 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153236 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153236 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153236 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000153236 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER METAST REV : 2017
000153236 9141_ $$y2019
000153236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd68f49dada874ac262fadf9fde869df$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000153236 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000153236 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000153236 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x0
000153236 980__ $$ajournal
000153236 980__ $$aVDB
000153236 980__ $$aI:(DE-He78)L701-20160331
000153236 980__ $$aUNRESTRICTED